Movatterモバイル変換

Atrasentan

Izvor: Wikipedija

Atrasentan

(IUPAC) ime

(2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid

Klinički podaci

Identifikatori

CAS broj

nije dodeljen

PubChem^[1]^[2]

Hemijski podaci

C₂₉H₃₈N₂O₆

510.621 g/mol

InChI
InChI=1S/C29H38N2O6/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34)/t23-,27-,28+/m1/s1^Y Key: MOTJMGVDPWRKOC-QPVYNBJUSA-N^Y

Farmakoinformacioni podaci

Trudnoća

Atrasentan je eksperimentalnilek koji se ispituje kao mogući tretman za razne tipoveraka^[4], među kojima je irak pluća ne-malih ćelija.^[5]

On jeantagonist endotelinkog receptora‎‎ selektivan zatip A (ET_A). Dok drugi lekovi ovog tipa (sitaksentan,ambrisentan) iskorištavajuvazokonstriktivna svojstva endotelina i uglavnom se koriste za lečenje plućne arterijske hipertenzije, atrasentan blokiraendotelinom indukovanućelijsku proliferaciju.

↑Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑„Atrasentan, entry in the public domain NCI Dictionary of Cancer Terms”. Arhivirano izoriginala na datum 2009-05-10. Pristupljeno 2014-04-05.
↑Chiappori, AA; Haura, E; Rodriguez, FA; Boulware, D; Kapoor, R; Neuger, AM; Lush, R; Padilla, B i dr.. (2008-03-01). „Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer”. Clinical Cancer Research 14 (5): 1464–1469. DOI:10.1158/1078-0432.CCR-07-1508. PMID 18316570.

	Portal Medicina
	Portal Hemija

Sakrivena kategorija: